Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy

Andy Andy; Robertus Bebet Prasetyo

Authors

Andy Andy
Robertus Bebet Prasetyo

Keywords:

LHRH agonist, prostate cancer, prostate-specific antigen, drug efficacy

Abstract

Abstract not found

Downloads

How to Cite

Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy. (2019). Global Journal of Medical Research, 19(F6), 17-20. https://medicalresearchjournal.org/index.php/GJMR/article/view/1872

Download Citation

References

Otis Brawley (2012) Prostate cancer epidemiology in the United States. 30(2), 195-200.

M Parkin, S Whelan, J Ferlay, L Rteppo, D Thomas (2002) Cancer incidence in five continents(Volume VIII). 155, 1-781.

R Siegel, E Ward, O Brawley, A Jemal (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. 61(4), 212-236.

Charles Huggins, Clarence Hodges (1941) Studies on Prostatic Cancer. 1(4), 9-12.

Osamu Ishizuka, Osamu Nishizawa, Shuji Nishizawa, Tomoya Satoh, Masahisa Wajiki, Hideo Kiyokawa, Yoshihiro Inoue, Shinya Kobayashi, Hiroya Mizusawa, Tatsuo Nakagawa (2013) Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. 18(3), 524-530.

Valdo Solang, Alwin Monoarfa, Ferdinand Tjandra (2013) Profil penderita kanker prostat di RSUP Prof. Dr. R. D. Kandou Manado periode tahun 2013-2015. 4(2), 15-16.

N Clarke, M De Santis, A Costello, Y-H Chang, T Pickles, A Pompeo, S Bazarbashi, G Haas, M Cooperberg (2016) Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa. 27(6), vi253.

B Hellerstedt, K Pienta (2009) The Current State of Hormonal Therapy for Prostate Cancer. 52(3), 154-179.

Patrizia Limonta, Marina Marelli, Roberta Moretti (2001) LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. 10(4), 709-720.

Hein Van Poppel, Laurence Klotz (2012) Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists. 19(7), 594-601.

P O'brien M F, Cronin A M, Fearn, B Smith, J Stasi, B Guillonneau (2009) Pretreatment prostatespecific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. 27(22), 3591-3597.

D Palma, S Tyldesley, P Blood, M Liu, J Morris, T Pickles (2007) Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. 67(5), 1425-1429.

T Choueiri, W Xie, D' Amico, R Ross, J C Hu, M Pomerantz (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. 115, 981-987.

Fabio Cury, Daniel Hunt, Mack Roach, William Shipley, Elizabeth Gore, I‐chow Hsu, Robert Krisch, Michael Seider, Howard Sandler, Colleen Lawton (2013) Prostate‐specific antigen response after short‐term hormone therapy plus external‐beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. 119(11), 1999-2004.

Élcio Silva, Ubirajara Ferreira, Wagner Matheus, Eliney Faria, Gustavo Silva, Minori Saito, Auro De Souza, Azuil Laranjo, Otavio Clark, Luis Magna, Lísias Castilho, Leonardo Reis (2012) Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. 44(4), 1039-1044.

Yasuhisa Fujii, Junji Yonese, Satoru Kawakami, Shinya Yamamoto, Yuhei Okubo, Iwao Fukui (2008) Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. 101(9), 1096-1100.